​

PT Pyridam Farma Tbk

IDX:PYFA Stock Report

Market Cap: Rp2.7t

Pyridam Farma (PYFA) Stock Overview

Engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. More details

PYFA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Risk Analysis

Earnings have declined by 45% per year over past 5 years

Has less than 1 year of cash runway

Volatile share price over the past 3 months compared to the ID market


PYFA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

PT Pyridam Farma Tbk Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pyridam Farma
Historical stock prices
Current Share PriceRp242.00
52 Week HighRp338.00
52 Week LowRp89.00
Beta1.25
1 Month Change3.42%
3 Month Change52.20%
1 Year Change124.07%
3 Year Change-76.84%
5 Year Change-63.33%
Change since IPO-13.57%

Recent News & Updates

Recent updates

Shareholder Returns

PYFAID PharmaceuticalsID Market
7D5.2%0.3%1.0%
1Y124.1%1.8%-4.3%

Return vs Industry: PYFA exceeded the ID Pharmaceuticals industry which returned 0.1% over the past year.

Return vs Market: PYFA exceeded the ID Market which returned -4.3% over the past year.

Price Volatility

Is PYFA's price volatile compared to industry and market?
PYFA volatility
PYFA Average Weekly Movement9.7%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement6.3%
10% most volatile stocks in ID Market13.4%
10% least volatile stocks in ID Market3.3%

Stable Share Price: PYFA's share price has been volatile over the past 3 months compared to the ID market.

Volatility Over Time: PYFA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of ID stocks.

About the Company

FoundedEmployeesCEOWebsite
19761,966Yan Gwan Leewww.pyfa.co.id

PT Pyridam Farma Tbk engages in the development, production, and trading of pharmaceuticals primarily in Indonesia. The company operates through Pharmaceutical Products, Esthetic, and Toll Manufacturing Services; and Medical Equipments segments. It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper.

PT Pyridam Farma Tbk Fundamentals Summary

How do Pyridam Farma's earnings and revenue compare to its market cap?
PYFA fundamental statistics
Market capRp2.72t
Earnings (TTM)-Rp377.73b
Revenue (TTM)Rp2.45t
1.1x
P/S Ratio
-7.2x
P/E Ratio

Is PYFA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PYFA income statement (TTM)
RevenueRp2.45t
Cost of RevenueRp1.81t
Gross ProfitRp647.76b
Other ExpensesRp1.03t
Earnings-Rp377.73b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-33.62
Gross Margin26.39%
Net Profit Margin-15.39%
Debt/Equity Ratio364.0%

How did PYFA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/09 04:14
End of Day Share Price 2025/07/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PT Pyridam Farma Tbk is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elvira NataliaPT Sinarmas Sekuritas